Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Retinal-related diseases
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
Genetically Humanized Mouse Models: Bridging Human Biology and Translational Research
LIVE WEBINAR
Genetically Humanized Mouse Models: Bridging Human Biology and Translational Research
Conventional partial humanized mouse strains fail to replicate complete human gene regulation and splicing behavior, creating a critical translational divide between preclinical testing and human clinical outcomes. Attendees will explore validated case studies across metabolic, cardiovascular, neurological and rare disease gene therapy programs, alongside our full suite of end-to-end preclinical CRO capabilities powered by TurboKnockoutᵀᴹ editing technology.
DATE
September 11 , 2026 | 9:00 - 10:00 AM PDT
LOCATION
Online

Introduction

Genetically humanized mice are indispensable tools for disease modeling and target validation. However, traditional models that only replace isolated coding sequences often lack the full human gene regulatory networks and splicing contexts—creating a critical translational divide between preclinical testing and clinical outcomes.
This session introduces fully genomically humanized mice built with the HUGO-GT™ (HUmanized Genomic Ortholog for Gene Therapy) platform. By swapping entire mouse genes for complete human genomic orthologs, these models successfully restore native human gene expression. Join us to explore how these advanced models overcome traditional bottlenecks and see real-world applications across ASO, siRNA, and gene therapy programs

Summary

This webinar is designed to address the key technical drawbacks of partial humanization strategies and showcase the transformative advantages of complete genomic humanization for academic and translational research. We will detail the end-to-end design workflow and explain how preserved human intronic, regulatory, and splicing sequences eliminate the critical gaps seen in limited coding-region-only lines.
Attendees will explore concrete applications of these models in gene therapy and drug discovery, highlighted through:
  • Targeted Case Studies: In-depth performance data for familial hypercholesterolemia and spinal muscular atrophy (SMA).
  • Therapeutic Modality Testing: Validating in vivo efficacy and clinical translatability for ASO, siRNA, and therapeutics.
  • Broad Indication Applications: Exploring our library of ready-to-use HUGO-GT™ models spanning neurological, ophthalmic, metabolic, cardiovascular, and rare disease research.
  • Advanced Model Generation: An overview of how TurboKnockout™ technology streamlines complex, large-fragment genomic knock-ins to create these humanized strains efficiently.
Who Should Attend
  • Principal Investigators and translational medicine researchers developing human disease animal models.
  • Gene therapy discovery scientists working with ASOs, siRNA, and oligonucleotide therapeutics.
  • Investigators studying rare diseases, neurology, ophthalmology, metabolic, and cardiovascular disorders.
  • Biotech program leaders validating novel therapeutic targets for clinical advancement.
Key Learning Objectives
  • Understand the strengths, limitations, and translational impacts of different humanization strategies.
  • Learn how fully genomically humanized models better recapitulate complex human gene biology (splicing and regulation).
  • Explore actionable applications of HUGO-GT™ models in gene therapy research and drug development.
  • Review real-world case studies demonstrating in vivo efficacy and translational impact across multiple disease areas.

Webinar Presenter

{{value.name}}
{{value.title}}
{{value.company}}
{{value.descript}}

Discover Our Solutions

{{ value.label }}
{{ value.name }}
Explore
Request Information About This Webinar
Whether you're joining live or catching up later, fill out the form to receive materials or updates related to this webinar.
Meeting Details
Which type of solutions are you considering?
When are you planning to start your project?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Main Area of Research
How did you hear about us?
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research